NASDAQ:PLSE Pulse Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pulse Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.59 +0.03 (+0.26 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$11.36Now: $11.59▼$11.8150-Day Range$9.27MA: $10.65▼$13.1452-Week Range$5.11Now: $11.59▼$17.45Volume47,836 shsAverage Volume109,294 shsMarket Capitalization$292.21 millionP/E RatioN/ADividend YieldN/ABeta1.9 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPulse Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Pulse Biosciences has a forecasted upside of 38.1% from its current price of $11.59.Amount of Analyst CoveragePulse Biosciences has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesPulse Biosciences has received 232 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPulse Biosciences has received 204 “underperform” votes. (Add your “underperform” vote.)Community SentimentPulse Biosciences has received 53.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote “Outperform” if you believe PLSE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLSE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,765.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders49.80% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.63% of the stock of Pulse Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulse Biosciences are expected to grow in the coming year, from ($1.98) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulse Biosciences has a P/B Ratio of 7.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLSE Previous Symbol CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone510-906-4600Debt Debt-to-Equity Ratio0.26 Current Ratio7.91 Quick Ratio7.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book7.83Profitability EPS (Most Recent Fiscal Year)($2.26) Net Income$-46,970,000.00 Net MarginsN/A Return on Equity-143.55% Return on Assets-107.81%Miscellaneous Employees54 Outstanding Shares25,212,000Market Cap$292.21 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $11.59 +0.03 (+0.26 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PLSE News and Ratings via Email Sign-up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter. Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions How has Pulse Biosciences' stock price been impacted by COVID-19 (Coronavirus)? Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PLSE shares have increased by 82.2% and is now trading at $11.59. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Pulse Biosciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pulse Biosciences. When is Pulse Biosciences' next earnings date? Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Pulse Biosciences. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences Inc (NASDAQ:PLSE) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.03. View Pulse Biosciences' earnings history. What price target have analysts set for PLSE? 1 brokerages have issued twelve-month price targets for Pulse Biosciences' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate Pulse Biosciences' stock price to reach $16.00 in the next year. This suggests a possible upside of 38.1% from the stock's current price. View analysts' price targets for Pulse Biosciences. Who are some of Pulse Biosciences' key competitors? Some companies that are related to Pulse Biosciences include Atrion (ATRI), Luminex (LMNX), Cerus (CERS), GenMark Diagnostics (GNMK), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Acutus Medical (AFIB), MiMedx Group (MDXG), Cryolife (CRY), Vapotherm (VAPO), SI-Bone (SIBN), LeMaitre Vascular (LMAT), Tactile Systems Technology (TCMD), Invo Bioscience (IVOB) and AVITA MED LTD/S (RCEL). View all competitors. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Canopy Growth (CGC), Enphase Energy (ENPH) and Novavax (NVAX). Who are Pulse Biosciences' key executives? Pulse Biosciences' management team includes the following people: Mr. Darrin R. Uecker, Pres, CEO & Director (Age 53)Mr. Brian B. Dow, CFO, Sr. VP of Fin. & Admin., Treasurer and Sec. (Age 50)Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 59)Dr. Richard Nuccitelli Ph.D., Chief Science OfficerDr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy When did Pulse Biosciences IPO? (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO. What is Pulse Biosciences' stock symbol? Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE." Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nuveen Asset Management LLC (0.27%), First Republic Investment Management Inc. (0.20%), Griffin Asset Management Inc. (0.17%), Bank of New York Mellon Corp (0.20%), Westside Investment Management Inc. (0.17%) and Charles Schwab Investment Management Inc. (0.13%). View institutional ownership trends for Pulse Biosciences. Which major investors are selling Pulse Biosciences stock? PLSE stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Griffin Asset Management Inc.. View insider buying and selling activity for Pulse Biosciences. Which major investors are buying Pulse Biosciences stock? PLSE stock was purchased by a variety of institutional investors in the last quarter, including TIAA FSB, Nuveen Asset Management LLC, Spotlight Asset Group Inc., Integrated Advisors Network LLC, Bank of New York Mellon Corp, Westside Investment Management Inc., First Republic Investment Management Inc., and Captrust Financial Advisors. View insider buying and selling activity for Pulse Biosciences. How do I buy shares of Pulse Biosciences? Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pulse Biosciences' stock price today? One share of PLSE stock can currently be purchased for approximately $11.59. How big of a company is Pulse Biosciences? Pulse Biosciences has a market capitalization of $292.21 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe. What is Pulse Biosciences' official website? The official website for Pulse Biosciences is www.pulsebiosciences.com. How can I contact Pulse Biosciences? Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
